Trial Profile
A Phase 1a/1b Study of an Anti-IDO-1 Agent (LY3381916) Administered Alone or in Combination With Anti- PD-L1 Checkpoint Antibody (LY3300054) in Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Lodapolimab (Primary) ; LY 3381916 (Primary)
- Indications Advanced breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 04 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 20 Feb 2020 Planned End Date changed from 18 Feb 2022 to 7 May 2020.
- 20 Feb 2020 Status changed from recruiting to active, no longer recruiting.